The Importance of Clinical Trials in Myeloma image

The Importance of Clinical Trials in Myeloma

Sep 20, 2023
06:30PM - 08:00PM MDT
Online Event
Overview

Dr. John Burke joins the Mountain West Myeloma Community to talk about the importance of clinical trials. What are common clinical trial myths that our community still believes? What hindrances keep myeloma patients from participating in clinical trials? What clinical trials are open and available in our region?

Learn with us and come with your questions for a great discussion.

Agenda
6:30 PM
Introductions
Audrey Burton-Bethke

Audrey introduces the agenda of the event and our featured speaker Dr. John Burke.

6:35 PM
Presentation
Dr. John Burke

Dr. John Burke talks about the importance of clinical trials.

7:05 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

7:35 PM
Announcements and Post Meeting Mingle
Audience
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Dr. John Burke

Dr. John Burke

Dr. John Burke is a board-certified hematologist and medical oncologist who joined Rocky Mountain Cancer Centers in 2003. He specializes in blood cancers, with an emphasis on lymphoid disorders, including lymphomas, chronic lymphocytic leukemia (CLL), and multiple myeloma. Dr. Burke is considered a national and international expert in blood cancers, lecturing primarily on lymphoid malignancies. He is very active in clinical research, helping to develop new therapies for lymphoid malignancies, and has published numerous articles in peer-reviewed medical journals, including the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology. Dr. Burke contributes to maximizing the quality of medical publications, serving as Editor-in-Chief for Targeted Therapies in Oncology and as an Associate Editor for JCO Oncology Practice. He is active in hematology and oncology professional societies, having recently served a term on the Ethics Committee of the American Society of Clinical Oncology (ASCO) and currently serving a term on the Committee on Practice of the American Society of Hematology (ASH).